{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:22:19Z","timestamp":1790767339813,"version":"4.1.0"},"reference-count":109,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,6,2]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.<\/jats:p><jats:p>Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pulmonary arterial hypertension is an uncommon but serious complication of dasatinib, which is often reversible upon discontinuation. Bosutinib and ponatinib have also been associated with pulmonary arterial hypertension, while imatinib has not. Rarely, interstitial lung disease has been associated with TKIs, predominantly with imatinib.<\/jats:p><jats:p>Mechanistically, dasatinib affects maintenance of normal pulmonary endothelial integrity by generating mitochondrial oxidative stress, inducing endothelial apoptosis and impairing vascular permeability in a dose-dependent manner. The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.<\/jats:p>","DOI":"10.1183\/13993003.00279-2020","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T19:04:33Z","timestamp":1591902273000},"page":"2000279","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors"],"prefix":"10.1183","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-4575","authenticated-orcid":false,"given":"Jason","family":"Weatherald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bondeelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Camille","family":"Chaumais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-4452","authenticated-orcid":false,"given":"Christophe","family":"Guignabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-8975","authenticated-orcid":false,"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ja\u00efs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-1951","authenticated-orcid":false,"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"2024102101463379000_56.4.2000279.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020777"},{"key":"2024102101463379000_56.4.2000279.2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2024102101463379000_56.4.2000279.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"2024102101463379000_56.4.2000279.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"2024102101463379000_56.4.2000279.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"2024102101463379000_56.4.2000279.6","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.61"},{"key":"2024102101463379000_56.4.2000279.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"2024102101463379000_56.4.2000279.8","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"2024102101463379000_56.4.2000279.9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ddtec.2013.12.001","article-title":"New resistance mechanisms for small molecule kinase inhibitors of Abl kinase","volume":"11","author":"Modugno","year":"2014","journal-title":"Drug Discov Today Technol"},{"key":"2024102101463379000_56.4.2000279.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8853"},{"key":"2024102101463379000_56.4.2000279.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"2024102101463379000_56.4.2000279.12","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102101463379000_56.4.2000279.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3563"},{"key":"2024102101463379000_56.4.2000279.14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.celrep.2015.12.080","article-title":"Kinase inhibitor profiling reveals unexpected opportunities to inhibit disease-associated mutant kinases","volume":"14","author":"Duong-Ly","year":"2016","journal-title":"Cell Reports"},{"key":"2024102101463379000_56.4.2000279.15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102101463379000_56.4.2000279.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2236"},{"key":"2024102101463379000_56.4.2000279.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"2024102101463379000_56.4.2000279.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01410-2016"},{"key":"2024102101463379000_56.4.2000279.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00217-2017"},{"key":"2024102101463379000_56.4.2000279.20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"2024102101463379000_56.4.2000279.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86249"},{"key":"2024102101463379000_56.4.2000279.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01096-2017"},{"key":"2024102101463379000_56.4.2000279.23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"2024102101463379000_56.4.2000279.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"2024102101463379000_56.4.2000279.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00745-2017"},{"key":"2024102101463379000_56.4.2000279.26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fphys.2018.00537","article-title":"Rho-kinase inhibition ameliorates dasatinib-induced endothelial dysfunction and pulmonary hypertension","volume":"9","author":"Fazakas","year":"2018","journal-title":"Front Physiol"},{"key":"2024102101463379000_56.4.2000279.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.01.007"},{"key":"2024102101463379000_56.4.2000279.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01694-2017"},{"key":"2024102101463379000_56.4.2000279.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00211811"},{"key":"2024102101463379000_56.4.2000279.30","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1144"},{"key":"2024102101463379000_56.4.2000279.31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12931-019-1074-2","article-title":"Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices","volume":"20","author":"Rieg","year":"2019","journal-title":"Respir Res"},{"key":"2024102101463379000_56.4.2000279.32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-017-0514-0","article-title":"Imatinib relaxes the pulmonary venous bed of guinea pigs","volume":"18","author":"Maih\u00f6fer","year":"2017","journal-title":"Respir Res"},{"key":"2024102101463379000_56.4.2000279.33","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0371OC"},{"key":"2024102101463379000_56.4.2000279.34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00329.2013"},{"key":"2024102101463379000_56.4.2000279.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02472-2018"},{"key":"2024102101463379000_56.4.2000279.36","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"2024102101463379000_56.4.2000279.37","doi-asserted-by":"crossref","unstructured":"Darvishi B , Farahmand L , Eslami-S Z , et al. NF-\u03baB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. Tumour Biol 2017; 39: 1010428317706919. doi:10.1177\/1010428317706919","DOI":"10.1177\/1010428317706919"},{"key":"2024102101463379000_56.4.2000279.38","doi-asserted-by":"crossref","first-page":"E1363","DOI":"10.3390\/molecules24071363","article-title":"Ponatinib inhibits proliferation and induces apoptosis of liver cancer cells, but its efficacy is compromised by its activation on PDK1\/Akt\/mTOR signaling","volume":"24","author":"Liu","year":"2019","journal-title":"Molecules"},{"key":"2024102101463379000_56.4.2000279.39","doi-asserted-by":"publisher","DOI":"10.1124\/mol.113.088005"},{"key":"2024102101463379000_56.4.2000279.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"2024102101463379000_56.4.2000279.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"2024102101463379000_56.4.2000279.42","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1200-7"},{"key":"2024102101463379000_56.4.2000279.43","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"},{"key":"2024102101463379000_56.4.2000279.44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","article-title":"Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia","volume":"7","author":"Mita","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"2024102101463379000_56.4.2000279.45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"2024102101463379000_56.4.2000279.46","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/bcp.13693","article-title":"Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase","volume":"84","author":"Mah\u00e9","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2024102101463379000_56.4.2000279.47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491423"},{"key":"2024102101463379000_56.4.2000279.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"2024102101463379000_56.4.2000279.49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188987"},{"key":"2024102101463379000_56.4.2000279.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"2024102101463379000_56.4.2000279.51","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib 50\u2005mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"key":"2024102101463379000_56.4.2000279.52","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24155"},{"key":"2024102101463379000_56.4.2000279.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"2024102101463379000_56.4.2000279.54","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR"},{"key":"2024102101463379000_56.4.2000279.55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61295-7"},{"key":"2024102101463379000_56.4.2000279.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"2024102101463379000_56.4.2000279.57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/1817-1737.191871","article-title":"Dasatinib-induced pleural effusion: Chylothorax, an option to consider","volume":"11","author":"Ferreiro","year":"2016","journal-title":"Ann Thorac Med"},{"key":"2024102101463379000_56.4.2000279.58","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10637-020-00932-3","article-title":"Dasatinib-induced chylothorax: report of a case and review of the literature","volume":"38","author":"Chen","year":"2020","journal-title":"Invest New Drugs"},{"key":"2024102101463379000_56.4.2000279.59","doi-asserted-by":"crossref","first-page":"e231653","DOI":"10.1136\/bcr-2019-231653","article-title":"Chylothorax: complication attributed to dasatinib use","volume":"12","author":"Al-Abcha","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2024102101463379000_56.4.2000279.60","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1164\/rccm.201806-1155IM","article-title":"Tyrosine kinase inhibitor-associated fibrothorax","volume":"199","author":"Adrianza","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101463379000_56.4.2000279.61","first-page":"851","article-title":"[A case of drug-induced organizing pneumonia caused by dasatinib]","volume":"45","author":"Sato","year":"2018","journal-title":"Gan To Kagaku Ryoho"},{"key":"2024102101463379000_56.4.2000279.62","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600555868"},{"key":"2024102101463379000_56.4.2000279.63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.1981"},{"key":"2024102101463379000_56.4.2000279.64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.resinv.2019.06.002","article-title":"Interstitial pneumonitis associated with dasatinib: two case reports and literature review","volume":"57","author":"Ito","year":"2019","journal-title":"Respir Investig"},{"key":"2024102101463379000_56.4.2000279.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2024102101463379000_56.4.2000279.66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0022-3859.194227","article-title":"Imatinib-induced pleural effusion: a case report","volume":"63","author":"Banka","year":"2017","journal-title":"J Postgrad Med"},{"key":"2024102101463379000_56.4.2000279.67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00347.x"},{"key":"2024102101463379000_56.4.2000279.68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.99.179"},{"key":"2024102101463379000_56.4.2000279.69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.20319","article-title":"Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy","volume":"79","author":"Rajda","year":"2005","journal-title":"Am J Hematol"},{"key":"2024102101463379000_56.4.2000279.70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04833.x"},{"key":"2024102101463379000_56.4.2000279.71","doi-asserted-by":"crossref","first-page":"e14402","DOI":"10.1097\/MD.0000000000014402","article-title":"Imatinib-induced irreversible interstitial lung disease: A case report","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2024102101463379000_56.4.2000279.72","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404207"},{"key":"2024102101463379000_56.4.2000279.73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12185-014-1666-z","article-title":"ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia","volume":"100","author":"Yoshimura","year":"2014","journal-title":"Int J Hematol"},{"key":"2024102101463379000_56.4.2000279.74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-017-2225-1","article-title":"Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials","volume":"106","author":"Suh","year":"2017","journal-title":"Int J Hematol"},{"key":"2024102101463379000_56.4.2000279.75","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1398-5"},{"key":"2024102101463379000_56.4.2000279.76","doi-asserted-by":"crossref","first-page":"203939","DOI":"10.1155\/2014\/203939","article-title":"Pleural effusion: a rare side effect of nilotinib-a case report","volume":"2014","author":"Usk\u00fcdar Teke","year":"2014","journal-title":"Case Rep Med"},{"key":"2024102101463379000_56.4.2000279.77","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171249"},{"key":"2024102101463379000_56.4.2000279.78","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728"},{"key":"2024102101463379000_56.4.2000279.79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.13801","article-title":"Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib","volume":"172","author":"Br\u00fcmmendorf","year":"2016","journal-title":"Br J Haematol"},{"key":"2024102101463379000_56.4.2000279.80","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00930-2017"},{"key":"2024102101463379000_56.4.2000279.81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00277-017-3144-1","article-title":"Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series","volume":"97","author":"Iurlo","year":"2018","journal-title":"Ann Hematol"},{"key":"2024102101463379000_56.4.2000279.82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jjcc.2019.07.008","article-title":"The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia","volume":"75","author":"Aoyama","year":"2020","journal-title":"J Cardiol"},{"key":"2024102101463379000_56.4.2000279.83","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2024102101463379000_56.4.2000279.84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-018-3507-2","article-title":"Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients","volume":"98","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Ann Hematol"},{"key":"2024102101463379000_56.4.2000279.85","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00277-019-03802-y","article-title":"Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy","volume":"98","author":"Tiribelli","year":"2019","journal-title":"Ann Hematol"},{"key":"2024102101463379000_56.4.2000279.86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12185-012-1250-3","article-title":"Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data","volume":"97","author":"Dao","year":"2013","journal-title":"Int J Hematol"},{"key":"2024102101463379000_56.4.2000279.87","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/10428194.2011.606940","article-title":"Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib","volume":"53","author":"Delomas","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2024102101463379000_56.4.2000279.88","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"2024102101463379000_56.4.2000279.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"2024102101463379000_56.4.2000279.90","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415"},{"key":"2024102101463379000_56.4.2000279.91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003889"},{"key":"2024102101463379000_56.4.2000279.92","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01004-2016"},{"key":"2024102101463379000_56.4.2000279.93","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/2045893217733444","article-title":"A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib","volume":"7","author":"Seegobin","year":"2017","journal-title":"Pulm Circ"},{"key":"2024102101463379000_56.4.2000279.94","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01110-2015"},{"key":"2024102101463379000_56.4.2000279.95","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1103-0"},{"key":"2024102101463379000_56.4.2000279.96","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2024102101463379000_56.4.2000279.97","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"2024102101463379000_56.4.2000279.98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"2024102101463379000_56.4.2000279.99","first-page":"ytz025","article-title":"Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report","volume":"3","author":"Toya","year":"2019","journal-title":"Eur Heart J Case Rep"},{"key":"2024102101463379000_56.4.2000279.100","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis & Rheumatol"},{"key":"2024102101463379000_56.4.2000279.101","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cjca.2019.08.002","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"35","author":"Orlikow","year":"2019","journal-title":"Can J Cardiol"},{"key":"2024102101463379000_56.4.2000279.102","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24174"},{"key":"2024102101463379000_56.4.2000279.103","first-page":"999","article-title":"Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia","volume":"57","author":"Morishita","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"2024102101463379000_56.4.2000279.104","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024102101463379000_56.4.2000279.105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"2024102101463379000_56.4.2000279.106","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"2024102101463379000_56.4.2000279.107","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/2045893217716659","article-title":"Combination targeted pulmonary hypertension therapy in the resolution of dasatinib-associated pulmonary arterial hypertension","volume":"7","author":"Jose","year":"2017","journal-title":"Pulm Circ"},{"key":"2024102101463379000_56.4.2000279.108","first-page":"3895197","article-title":"Dasatinib-induced pulmonary arterial hypertension treated with upfront combination therapy","volume":"2018","author":"Nishimori","year":"2018","journal-title":"Case Rep Cardiol"},{"key":"2024102101463379000_56.4.2000279.109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MCP.0000000000000412","article-title":"Pulmonary arterial hypertension induced by tyrosine kinase inhibitors","volume":"23","author":"Weatherald","year":"2017","journal-title":"Curr Opin Pulm Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00279-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:34:36Z","timestamp":1740382476000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00279-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":109,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,10,29]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1183\/13993003.00279-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00279-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]}}}